Member Info for LlamaFarmer

Dibs - hope you are well and have only dipped a toe back in here.

PKB - one of their customers is the NHS - specialist Kidney units - it's another freebie to try and get into the NHS.

I might be wrong and the Co. Nomad said "No Tom that company making contract you just landed with 6m paying clients isn't material and doesn't need to be RNS to tell the investors of this new income stream."

Or I might be right and this is the fluff to get a decent sized placing underway? They need at least £4m a year to cover cash burn and a lump of that is on Executive salaries...

Dibs,

For clarification - PKB get paid - look at their online historic accounts for 2023 ( negative net worth ) , this in between set of ac's will be as the patients list grew from 1m to 6m in 2021 - 2025.

FDBK - My cynicism says, will have given their given their product away as a bolt on to get exposure to the 6m registered patients, 1 in 4 of whom log on monthly... that's why there is no RNS as it is not commercially sensitive information.

Good deal for PKB though.

If it doesn't have a commercial impact then doesn't need a RNS - they could pay to promote via a reach rns but that's a different product.

Assumption would be its another give away for free deal.

PKB is a free to use service - look up their accounts...

Has he got you listed on email as Vikram the ramper :) ??

If 002 does get linked to Spravato and then passes a phase 3 ... it will be a bigger product run than Spravato...

All still early days and pie in the sky, they've said we'll get the first data set around Q1 and may then needs more data to prove it up?

But, if it does or looks like it will - there are some big numbers to be crunched for an off license agreement.

Based on sales data and forecasts through early 2026, Spravato (esketamine) has established itself as a blockbuster drug for Janssen (Johnson & Johnson), with an annual revenue run rate exceeding $2 billion as of late 2025. If sold as a standalone asset, its value would be highly significant, likely in the range of many billions, driven by rapid growth, high demand, and projected peak annual sales of $3 billion to $5 billion.

Triple - Exactly that, in the forward guidance from November 2025 A.T. specifically said somewhere around Q1 2026, he didn't say within Q1, there is a distinction to be made there!

The share price is doing its own thing, imo not currently linked to the businesses progression.

Since then we have received the following 4 RNS - you could easily say all of these are around Q1!

28th Jan 2026 7:00 am RNS Expansion of SVN-015 into depression

7th Jan 2026 7:00 am RNS US Patent allowance for PTSD discovery programme

22nd Dec 2025 7:00 am RNS Research and Development Update - Q4 2025

3rd Dec 2025 7:00 am RNS SVN-015 accepted into US NIDA funded programme

So what we are waiting for are updates on 001 AUD out licencing, 002 AUD spravato bridging data and 014 ptsd choice of lead candidate, plus whatever else they were working on from the AI CNS library, maybe a 015 update from USA?

Paul Carters been there since rejoining in October 2025, be good to hear from him?

DVH ...

Are you talking about another stock or SVNS?

28th Jan 2026 7:00 am RNS Expansion of SVN-015 into depression

7th Jan 2026 7:00 am RNS US Patent allowance for PTSD discovery programme

22nd Dec 2025 7:00 am RNS Research and Development Update - Q4 2025

22nd Dec 2025 7:00 am RNS Research and Development Update – Q4 2025

3rd Dec 2025 7:00 am RNS SVN-015 accepted into US NIDA funded programme

It's easy enough to work this out without looking over your shoulder.

6,806,403,493. bn shares in issue

If a UK holder then over 3% is notifiable. 204192104.79 shares

If an offshore holder then over 5% is notifiable 340320174.65 shares.

Look at the earlier funding rounds of Awaken from North American and Canadian (and elsewhere) investors some UK ones pop up, others from North America don't so you can see that the 3 and 5% are being adhered to.

A.T. has advised that he went and sat with the ULNW investors recently so they are still holding and maybe some of them sold to other UHNW individuals but as under the limits you wont see a TR1 if they do transfer holdings to each other.

It is a fact that if you own 2.999% or 4.999% ( territory dependant ) you do not have to TR1.

Triplestar ... they rolled it again, must have liquidity. That'll flip at 0 28p, not enough to blip the charts.

Looking more balanced, most leverage must be closed and gone.

Couple of sessions to rebalance and ready to go again.

Looks like the sellers have reduced in size, in time from the melt down data point.

Lovely summary, it's even better than that.

Spravato is currently annualised at $2bn, last Quarter of 2025 it did over $500m, and set to grow to annual sales of $3 - 3.5bn

002 is a danger to them and of interest to their competition, as soon as it is cleared for 5052b i'd expect bids to come in which will be interesting as it looks like SVNS will still only be UK listed...

Michu... 0.22p at this size are sells, anything above is a buy.

Feels like the latest in the line of sellers finished yday?

As for a buyout they'd only need 30% to trigger it... thats maybe possible, getting the rest of the stock at a knock down, more problematic.

Talking to some of the % stockholders, everyones happy enough to hold to give A.T., Nutt and D.P some time.

The cornerstone investors all appear locked in.

This looks like what happens when a business changes juridstictions from Can to U.K. and then has a delay on its pipeline, sorting the wheat from the chaff.

Will do us all good when news does finally land, a tighter register = more explosive rerates.

"Seller having a Brazilian or having a nap 😂"

Beach full of them recently.

Someone's been picking up all of these sells for months... we can see that as if they hadn't the s.p. would have cratered.

A.T. said in his latest interview he went and met the U.S. Ultra High Net Worth investors recently at Mar A Lago. as these people are offshore they don't have to TR1 until 5%+, if there is a group of them picking up the stock that PI's and some of the weaker early doors investors are selling off then 2 + 2 = 4.

Who ever it is, someone believes in the future value and opportunities with Solvonis.

Then the 1.953m ... buy...

Dvh - look at the times and the prices, have live prices on both sides to check them against.

For example the 3m was a buy...

One interesting point flagged up then is how much the comparables , Mindmed, Atai, GH Research, and Gilgamesh, quoted by Solvonis on their Corporate deck ( see website ) spent on their drug trials.

Another example would be Johnson & Johnson on Spravato, something like 19 phase 1 trails and at least 3 of Phase 3 trails.

Solvonis walk in and are granted Bridging Data to enter a Phase 2b trial... Capital efficient business model at play!

You can look at it the other way as well?

This came up from 0.10p and is holding well at the midpoint of 0.25p ... it has been funded as high as 0.33p and been up to 0.39p.

The news flow has been building - the market hasn't revalued the business yet, as is waiting on developments that naturally take time to filter through.

There look to have been a few sellers - not surprising after first the change from Canadian to U.K. listing jurisdiction, then the recent margin calls across the markets.

Life Science businesses are generally well insulated against recessions.

When it was at 0.39p , the business didn't have 0.15a and 0.15b , didn't have the U.S. Govt funding for Meth and Coke, didn't have the SVN 014 USA patent allowance, didn't have as many patients in the more Kare trial than it does today.

Sentiment and markets are funny things.

As we saw with SVN-015, a novel compound emerging from its AI-enabled discovery programme, was accepted into the U.S. National Institute on Drug Abuse's ("NIDA") Addiction Treatment Discovery Program ("ATDP")

Under the programme, NIDA - part of the U.S. National Institutes of Health ("NIH") - will fund and conduct a standard package of preclinical safety and pharmacology studies, including cardiovascular risk assessment. Initial results are expected in Q1 2026. Subject to supportive outcomes, SVN-015 may progress into further NIDA-funded efficacy testing in validated models of methamphetamine and cocaine addiction.

That just arrived in a RNS, no spike the day before - check the chart, no nudge nudge, wink, winks given.

All this needs now is time, keep the reins tight on cashflow wastage.

Patent Cliff

Mergers & Acquisitions heating up in Life Sciences.

1.Progress pipeline with UK x 1 Govt funded assets and USA 4 X Govt funded assets.

2. That organically increases the UK market Capital, once that reaches a size that can be arbitraged successfully.

3.List on the Nasdaq with a decent funding round.

4.Sit back and watch it go - Pi's can sell to II's at their leisure.

RhHh - no flies on you ...

Andy,

The longer this goes towards full 280n take up, I'd hope they would keep this in house, 86% phase 2, NHS funded for Phase 3, what's the point of out licensing it for a few mill and some back end money when you can keep the lot, trial complete 2027, data read out 2027,/28 and 2029 latest for market roll out, , they must surely be tempted to hold on until data read out?

When it was just 001 and the sniff in the air of 002, then outlicensing 001 as a matter of urgency was a no brainer.

Now there is 001, 002, 014, 015a and 015b plus more to come ( RNS and interview with A.T. ) they have a golden opportunity to become a proper life sciences business, not just pumping out early stage molecules into big pharmas pockets.

Their ability to gain U.S. non dilutative funding to run each programme, plus the existing UK Govt/NHS money is a game changer i.m.o.

Look on their website at the Nasdaq listed peer companies, if they can get on there end of 2026/2027 then they have a genuine shot of rerating into a $750 - $1.5BN Pharma, a decent chunk of that value will be 001 for UK and Europe, if they keep it.

Look at the BOD taking stock and warrant positions recently, as we've seen with recent M & A activity these types of Co. vehicles get sold for silly money at a certain inflection point.

They now have Five opportunities to hit $1bn plus, 001 has a very high chance of success, 002, imo will be the same due to Spravato and other data on ketamin being well tolerated in trials and treatments, assuming it gets positive bridging data there are two decent jackpot opportunities, 014 is choosing its lead candidate, 015 Meth & Coke there should be some US reporting soon? plus 015 depression.

Guess it depends on your outlook, if you want a quick flip you'll want this out licensed, if you are in this for a life changing payout, you'll hope they keep everything?